What are the fundraising trends in the longevity market?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes publicly disclosed equity rounds raised by pure-play longevity companies across full-year 2024, full-year 2025, and year-to-date 2026 through May 2026. The dataset keeps only disclosed equity rounds of $300K or more, excludes undisclosed-amount rounds and non-equity financings, and applies a strict pure-play test for companies focused on healthspan, aging biology, biological-age measurement, lifespan extension, or longevity medicine.
The longevity market expanded sharply in 2025 before cooling in the freshest 2026 year-to-date window. Full-year 2024 produced 18 qualifying deals and $577.3M, full-year 2025 rose to 31 qualifying deals and $2.212B, while January through May 2026 produced 5 qualifying deals and $233.9M.
The 2026 decline is real, but it should be read against an unusually large 2025 comparison. Early 2025 was inflated by Retro Biosciences' reported $1B financing and Insilico Medicine's $110M Series E, while early 2026 is led by Loyal's $100M Series C, Life Biosciences' $80M Series D, and L-Nutra's $36.5M investment.
Capital in the longevity market remains highly concentrated. In year-to-date 2026, the top deal represents 42.8% of all capital and the top three deals represent 92.6%, which means the market's headline strength depends on a very small number of conviction rounds.
The typical 2026 longevity round is much larger than the seed checks at the bottom of the market but far smaller than the headline total might suggest. The median round is $36.5M, the average round is $46.78M, and the largest round is 2.74 times the median.
Longevity Therapeutics Developers are still the capital spine of the longevity market. They account for 3 of 5 year-to-date 2026 deals and $190.4M, or 81.4% of all capital, while Consumer Longevity Brands and Healthy Aging Clinics remain much smaller by dollars.
Late-stage and follow-on capital dominate the freshest period. Series B and later rounds account for $216.5M, or 92.6% of 2026 year-to-date capital, while Seed and Series A rounds account for only $17.4M, even though seed deals still represent 40.0% of deal count.
New company formation has not disappeared from the longevity market. First financings represent 40.0% of year-to-date 2026 deals, but only 7.4% of capital, which confirms that investors are still creating new options while reserving larger checks for companies with more proof.
North America remains the default scale geography. In year-to-date 2026, North America accounts for $226.9M, or 97.0% of capital, while Asia-Pacific contributes one $7.0M clinic round and Europe has no qualifying deal in the period.
The practical interpretation is that the longevity market is maturing at the top and still experimental underneath. Investors are not funding broad anti-aging narratives indiscriminately; they are funding companies that can translate longevity into regulated therapeutics, measurable interventions, clinical infrastructure, or medically grounded consumer products.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Is more or less capital going into the longevity market?
Less capital is going into the longevity market so far in 2026 than over the comparable year-to-date period in 2025, but the longer comparison still shows a market that became much larger in 2025 than it was in 2024. January through May 2026 produced about $234M across 5 qualifying deals, down from about $1.18B across 6 qualifying deals over the same early-year window in 2025.
The direct answer is therefore negative for the freshest period. The longevity market is receiving less capital right now than it did during the same early part of 2025, and that is not just a rounding difference.
The honest interpretation is more nuanced. Early 2025 was unusually inflated because Retro Biosciences was reported to be raising $1B and Insilico Medicine closed a $110M Series E. Those two rounds made the early-2025 longevity market look much larger than a normal operating baseline.
So far in 2026, the largest deals are Loyal's $100M Series C, Life Biosciences' $80M Series D, and L-Nutra's $36.5M investment. Those are serious financings, but they do not recreate the one-off scale of Retro.
The practical takeaway is that the longevity market looks cooler in 2026, not abandoned. Full-year 2025 still marked a major expansion versus 2024, but the latest data says investors have become more selective about writing exceptionally large longevity checks.
Is longevity funding activity driven by more deals or larger rounds?
Longevity funding activity is currently driven more by larger rounds than by a broad increase in deal count. In year-to-date 2026, only 5 qualifying deals generated $233.9M, and the top three deals captured 92.6% of all capital.
That means the longevity market is not being lifted by dozens of companies each raising moderate checks. The market is being pulled upward by a few large financings, especially Loyal, Life Biosciences, and L-Nutra.
The full-year 2025 comparison makes the same point in a different way. Deal count increased from 18 deals in 2024 to 31 deals in 2025, so the market did broaden. But capital grew much faster, from $577.3M to $2.212B, because a small number of outsized rounds changed the total.
This is exactly the kind of market where average round size can mislead. The 2025 median round was about $12M, close to the 2024 median of $11.9M, while the average round jumped from $32.1M to $71.4M. The real signal is not that every company raised more; it is that the largest companies raised much more.
For deeper analysis of deal-size concentration and round distribution, see the full longevity market report.
Is longevity capital moving toward later-stage or earlier-stage companies?
Longevity capital is moving toward later-stage companies in the freshest 2026 period, even though new company formation remains visible. Series B and later rounds captured $216.5M, or 92.6% of year-to-date 2026 capital, while Seed and Series A captured only $17.4M.
The deal-count picture is less one-sided. Seed rounds represent 2 of 5 deals, or 40.0% of activity, which means early-stage formation is still happening. But the larger checks are going to follow-on companies with more established stories.
This creates a barbell shape. New concepts can still raise seed rounds, and mature assets can still attract large capital, but the middle of the market is thin. The absence of Series A and Series B rounds in year-to-date 2026 is one of the clearest warning signs in the dataset.
Compared with 2025, the stage picture is also distorted by Retro Biosciences. Retro's reported financing was classified as Series A or unknown, which made the 2025 market look more early-stage by dollars than it probably was in economic substance.
The practical takeaway is that the longevity market is not anti-seed. It is anti-undifferentiated seed. Early-stage companies can still get funded, but large checks require proof of regulatory path, clinical relevance, platform depth, or institutional credibility.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Is the longevity market maturing or still experimental?
The longevity market is maturing at the top, but it remains experimental in the long tail. The strongest maturity signal is the presence of large follow-on rounds, late-stage financings, and institutional investors around companies such as Loyal, Life Biosciences, L-Nutra, Function Health, NewLimit, BioAge, and Insilico Medicine.
Those are not casual wellness bets. They are companies tied to regulated products, cellular rejuvenation platforms, preventive-health infrastructure, AI drug discovery, or clinically scaffolded longevity interventions.
But the broader market is not mature in the way a conventional healthcare category is mature. In 2026 so far, the bottom two deals represent only 7.4% of capital, and the top three deals represent 92.6%. That gap between the top companies and everyone else is the real maturity test.
A mature market would show repeated mid-sized financings, standardized proof points, recurring specialist investors, and clearer stage progression. The longevity market has some of those ingredients, but not enough of them yet.
The best interpretation is a barbell market. A handful of companies are moving into serious institutional validation, while many others remain early scientific or commercial experiments.
Are new startups still entering the longevity market?
Yes, new startups are still entering the longevity market, but new entrants are not receiving most of the capital. In year-to-date 2026, first financings represent 2 of 5 deals, or 40.0% of deal count, but only $17.4M, or 7.4% of capital.
That means the longevity market is still producing new companies, but the dollar-weighted direction is being set by established follow-on companies. HexemBio and TMRW show that credible new entrants can raise seed capital, but their checks are small relative to Loyal, Life Biosciences, and L-Nutra.
The same pattern appeared in earlier periods. First financings represented 38.9% of 2024 deals and 35.5% of 2025 deals, but they captured less than 10% of capital in both years.
This consistency matters because it shows a structural split between formation and scale. Deal count tells us new companies are still entering the longevity market; capital share tells us those new companies are not defining the market yet.
For a deeper view of first financings, follow-on rounds, and new-company formation, see the longevity market deck.
Are more investors entering the longevity market?
More investors participated in the longevity market in 2025 than in 2024, but the 2026 year-to-date period does not yet show broad investor expansion. Full-year 2025 included roughly 85 to 100 unique disclosed investors, compared with about 84 named disclosed investors in 2024.
So the investor base broadened modestly, not explosively. The bigger change was investor composition: the longevity market attracted biotech specialists, generalist venture funds, corporate venture arms, sovereign or institutional capital, operator angels, and longevity specialists.
In 2026 so far, the disclosed investor base is much smaller because the sample has only 5 deals. The dataset identifies 11 named disclosed investors and 5 conservative tier-1 investors: Mubadala, age1, Baillie Gifford, Draper Associates, and SOSV.
That is a meaningful list, but it is not enough to prove broad ecosystem expansion in the current year. The absence of any disclosed investor appearing in more than one qualifying 2026 deal suggests the market is still deal-led rather than ecosystem-led.
The practical reading is that investors are entering the longevity market for specific credible companies, not necessarily deploying repeatedly across the whole category.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Are top investors getting more or less active in longevity?
Top investors are becoming more selective in the longevity market rather than uniformly more active. High-quality investors remain present, but repeat activity across multiple companies is limited.
In 2024, repeat disclosed investors included Lifespan Vision Ventures, Andreessen Horowitz Bio + Health, Eli Lilly, Hevolution, R42 Group, SeedFolio, and Sofinnova Investments. That showed a small but visible group of specialist and biotech investors making repeat longevity bets.
In 2025, top-investor activity was more concentrated around a few high-conviction opportunities, including NewLimit, Function Health, Insilico Medicine, Aeovian, and other larger rounds. Most investors still appeared only once.
So far in 2026, no disclosed investor appears in more than one qualifying deal. That freshness signal should not be overread because the sample is small, but it does show that top investors are not spraying capital broadly across the longevity market.
The honest interpretation is that a marquee investor on a longevity deal validates that company more than it validates the whole category. Top investors are still participating, but they are concentrating around regulated therapeutics, cell reprogramming, stem-cell rejuvenation, clinical endpoints, measurable biomarkers, and scalable preventive-health workflows.
Which longevity subcategories are gaining momentum?
The subcategory gaining the most durable momentum is Longevity Therapeutics Developers. Therapeutics captured 76.0% of capital in 2024, 75.4% in 2025, and 81.4% so far in 2026.
That consistency is the strongest subcategory signal in the whole market. Therapeutics also represented 55.6% of 2024 deals, 58.1% of 2025 deals, and 60.0% of 2026 year-to-date deals, so the category dominates both volume and dollars.
Preventive Health Platforms gained momentum in 2025, mostly because Function Health raised a $298M Series B. That made the category look much more scalable when testing, membership, AI health intelligence, and consumer distribution are combined in one platform.
Consumer Longevity Brands are also gaining selective momentum. Blueprint's $60M financing in 2025 and L-Nutra's $36.5M financing in 2026 show that consumer-facing longevity can attract capital when it has exceptional brand pull, medical-nutrition credibility, or clinical scaffolding.
The main conclusion is that therapeutics are the only category with durable momentum across every period. Preventive platforms and consumer longevity can break out, but their momentum is episodic and company-specific.
For more context on subcategory shifts across therapeutics, preventive platforms, clinics, diagnostics, consumer brands, and research platforms, see the market report covering longevity subcategories.
Which longevity subcategories are losing momentum?
Diagnostics Biomarker Companies and Aging Research Platforms are the clearest subcategories losing momentum in the freshest 2026 period. Neither category has a qualifying deal through May 2026 under the strict dataset filters.
Diagnostics are especially interesting because they are central to the longevity narrative but financially underweighted. Diagnostics Biomarker Companies captured only 1.4% of 2024 capital and 1.1% of 2025 capital, then disappeared from the qualifying 2026 year-to-date sample.
Aging Research Platforms also look weaker in 2026. The category raised $22.5M in 2024 and $115.6M in 2025, but the 2025 figure was heavily shaped by Insilico Medicine's $110M Series E. Without a large platform round, the category looks much smaller.
Healthy Aging Clinics are not exactly losing momentum, but they are failing to scale capital. Clinics had 2 deals and $48.5M in 2024, 3 deals and $32.3M in 2025, and 1 deal for $7.0M so far in 2026.
The practical takeaway is that diagnostics, research platforms, and clinics are not disappearing. They are being subordinated to therapeutics and large preventive platforms unless they can show a route to regulated product economics, longitudinal data advantage, or scalable delivery.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which regions are gaining momentum in longevity funding?
Asia-Pacific is the region gaining the most relative momentum in the full-year comparison, while North America remains dominant by absolute capital. Asia-Pacific moved from no qualifying deals in 2024 to 5 deals and about $305M in 2025.
That was a real shift because Asia-Pacific's 2025 activity included more than small consumer or clinic rounds. Insilico Medicine's $110M Series E and Minovia Therapeutics' $180M financing showed that the region could participate in capital-intensive longevity categories.
In year-to-date 2026, Asia-Pacific has one qualifying deal: TMRW's $7.0M seed round in Australia. That gives the region 20.0% of deal count but only 3.0% of capital in the current period.
North America also gained absolute momentum from 2024 to 2025, rising from $559.3M to $1.804B. Its share of capital fell because Asia-Pacific entered the market meaningfully, but that is not North American weakness; it is partial geographic diversification.
The best answer is that Asia-Pacific gained the most relative momentum in 2025, North America remains the scale center, and 2026 has not yet repeated Asia-Pacific's large-round breakout.
Which regions are losing momentum in longevity funding?
Europe has the weakest fresh signal in the longevity market. Europe had 4 qualifying deals in 2024 and 7 in 2025, but it has no qualifying deal in year-to-date 2026 through May.
That absence should be treated cautiously because the 2026 sample contains only 5 deals. Still, the fresh signal is clearly weak, especially because Europe had been consistently present in the prior two full-year periods.
The longer comparison is mixed rather than purely negative. Europe raised about $18M in 2024 and about $104M in 2025, so it did grow in absolute capital. But it remained underpowered relative to North America and Asia-Pacific.
In 2025, Europe represented 22.6% of deals but only 4.7% of capital. That means European longevity companies were active at formation stage but often lacked the large institutional-scale rounds seen in North America.
The practical interpretation is that Europe is not structurally absent from longevity, but it is undercapitalized and currently exposed to weaker momentum in research-platform and academic-biotech-style categories.
Is longevity becoming more global or regionally concentrated?
The longevity market became more global in 2025 versus 2024, but it has become regionally concentrated again in the early 2026 window. Full-year 2024 was overwhelmingly North American, with North America capturing 96.9% of capital and 77.8% of deals.
Full-year 2025 was more global. North America still led with 81.5% of capital and 61.3% of deals, but Asia-Pacific reached 13.8% of capital and Europe reached 22.6% of deal count.
The 2026 year-to-date picture reverses some of that diversification. North America accounts for 97.0% of capital and 80.0% of deals, Asia-Pacific accounts for one small clinic-platform deal, and Europe has no qualifying deal.
The useful distinction is between participation and capital depth. Europe and Asia-Pacific can produce longevity companies, but North America remains the main home for large rounds.
So the longevity market is becoming more global in participation, but not yet globally balanced in capital. The market is still regionally concentrated whenever the question is where the largest checks are being written.
For the full regional breakdown across North America, Europe, and Asia-Pacific, see the full market view on longevity geography.
This chart, featured in our longevity market deck, shows how wearable longevity devices have driven growth in the longevity market over time
Is longevity capital moving toward proven winners or new opportunities?
Longevity capital is moving toward proven winners much more than new opportunities, even though new opportunities are still entering the funnel. In year-to-date 2026, first financings are 40.0% of deals but only 7.4% of capital.
That gap is the clearest signal in the dataset. The longevity market consistently funds new opportunities, but new opportunities do not receive the largest checks.
Most capital goes to follow-on companies. In 2026 so far, follow-on rounds captured 92.6% of all capital, with the largest checks going to Loyal, Life Biosciences, and L-Nutra.
The same pattern appeared in prior years. In 2025, large capital clustered around Retro Biosciences, NewLimit, Function Health, Minovia, Insilico, Juvenescence, and Aeovian. In 2024, larger rounds clustered around BioAge, Alzheon, Function Health, Human Longevity, Arda, Rubedo, and Aeovian.
The most assertive reading is that the longevity market is not primarily a discovery-capital market right now. It is a validation-capital market: investors are still creating new options, but they reserve meaningful dollars for companies that already look like potential category winners.
Is the longevity market becoming winner-takes-most?
Yes, the longevity market is becoming winner-takes-most by capital, although not by deal count. The strongest evidence is concentration at the top of the funding table.
In 2025, the top deal captured 45.2% of all capital, the top three captured 66.8%, the top five captured 77.7%, and the top ten captured 90.2%. The bottom half of deals captured only 4.2% of capital.
The 2024 comparison shows that concentration was already high but intensified in 2025. In 2024, the top deal captured 29.4% of capital, the top three captured 56.0%, and the bottom half captured 8.5%.
So far in 2026, concentration remains extreme. The top three deals captured 92.6% of capital, while the bottom two deals captured only 7.4%.
The nuance is that the longevity market is not winner-takes-most by company count. Deal count expanded from 2024 to 2025, and first financings remain visible. But the dollar pool is increasingly captured by a small number of companies, which makes headline capital a poor indicator of the typical company's fundraising environment.
Is the next wave of longevity winners becoming visible?
Yes, the next wave of longevity winners is becoming visible, but the visibility is concentrated around companies that translate longevity into regulated therapeutics, measurable interventions, or scalable preventive-health infrastructure. The likely winner set is not the broad universe of companies using longevity language.
The most visible therapeutic winners include Loyal, Life Biosciences, NewLimit, Aeovian, BioAge, Retro Biosciences, Rubedo, Arda, Juvenescence, Minovia, Insilico, and potentially HexemBio. These companies stand out because they connect longevity to FDA pathways, epigenetic reprogramming, mTOR biology, senescence, cell depletion, AI drug discovery, mitochondrial therapies, or stem-cell rejuvenation.
Preventive-health winners are also visible, but there are fewer of them. Function Health is the standout because it moved from a $53M Series A in 2024 to a $298M Series B in 2025, which suggests investors see it as more than a narrow biomarker-testing product.
The next wave is less visible in diagnostics and clinics. Generation Lab, GlycanAge, NADMED, Circulate Health, TMRW, Human Longevity, Fountain Life, and Blue Longevity Clinic all point to demand for measurement and delivery infrastructure, but these categories have not yet shown the same capital density as therapeutics or Function-style preventive platforms.
The best conclusion is that the next wave of winners is visible, but not fully settled. The likely winners are companies that can turn aging from a narrative into a reimbursable, approvable, measurable, or scalable product category.
For more detail on the companies becoming visible as potential longevity winners, see the deeper analysis of the longevity market.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Is the longevity funding landscape fragmenting or consolidating?
The longevity funding landscape is consolidating by capital while fragmenting by company type and category participation. Capital is consolidating because a small number of companies capture most dollars.
In 2025, the top three deals captured 66.8% of capital and the top ten captured 90.2%. So far in 2026, the top three deals captured 92.6% of capital. Those figures are unambiguously consolidating.
At the same time, the market is fragmenting by business model. The qualifying companies now span therapeutics, preventive platforms, diagnostics, clinics, consumer longevity brands, and aging research platforms. Full-year 2025 had activity in all six categories, unlike 2024, when Consumer Longevity Brands had no qualifying deals.
The investor landscape is also fragmented. The market includes biotech VCs, generalist venture funds, corporate venture arms, sovereign or institutional capital, longevity specialists, operator angels, celebrity or public-figure investors, and strategic healthcare investors.
The correct synthesis is that the longevity market is consolidating around a few capital magnets while fragmenting across many experimental entry points. It is broad enough to support many theses, but not mature enough for capital to be evenly distributed across those theses.
Where is investor attention shifting in longevity?
Investor attention in the longevity market is shifting toward proof-heavy longevity: regulated therapeutics, measurable biological interventions, clinical or diagnostic infrastructure, and platforms that can convert aging biology into institutional-scale outcomes.
The strongest evidence is the continued dominance of Longevity Therapeutics Developers. Therapeutics captured 76.0% of capital in 2024, 75.4% in 2025, and 81.4% so far in 2026. Investors are not shifting away from therapeutics; they are doubling down on therapeutics as the core investable lane.
Within therapeutics, attention is moving toward mechanisms that can be framed as drug development rather than vague anti-aging. Loyal is tied to an FDA-regulated canine longevity drug, Life Biosciences is tied to partial epigenetic reprogramming, HexemBio is tied to blood stem-cell rejuvenation, and Aeovian is tied to mTORC1 biology.
Investor attention also shifted in 2025 toward preventive-health infrastructure, but this shift is concentrated rather than broad. Function Health's $298M Series B made Preventive Health Platforms the second-largest category in 2025 by capital.
Consumer longevity is gaining attention only when it is clinically scaffolded or brand-exceptional. Blueprint and L-Nutra show that consumer-facing longevity can attract capital, but they do not prove that generic supplement or wellness companies are broadly fundable.
The clearest answer is that investor attention is shifting away from longevity as a broad aspiration and toward longevity as a proof system. The highest-quality capital is following companies that can show biological mechanism, regulatory path, measurable endpoint, platform scale, or credible clinical delivery.
For real-time tracking of how investor attention is moving across longevity therapeutics, preventive platforms, diagnostics, clinics, and consumer brands, see the longevity market report.
All the funding deals in the longevity market from 2024 to Apr 2026
The table below lists every disclosed funding deal in the supplied longevity dataset between January 2024 and April 2026, sorted from the most recent deal to the oldest.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader investability view, see our longevity market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| Life Biosciences | Apr 2026 | Cellular rejuvenation therapies using partial epigenetic reprogramming to reverse or prevent multiple diseases of aging. | Longevity Therapeutics Developers | Series D+ | $80M | North America | Follow-on | Not disclosed | Life Biosciences |
| HexemBio | Apr 2026 | Blood stem-cell rejuvenation therapy targeting age-related decline in hematopoietic stem cells and immune-system function. | Longevity Therapeutics Developers | Seed | $10.4M | North America | First financing | Draper Associates; SOSV | SOSV |
| TMRW | Mar 2026 | Australian longevity membership and clinic platform combining biological data, epigenetic-age testing, clinical support, and long-term health optimization. | Healthy Aging Clinics | Seed | $7M | Asia-Pacific | First financing | None clearly tier-1 globally; Tidal Ventures is the lead | Longevity.Technology |
| Loyal | Feb 2026 | FDA-regulated canine longevity drugs intended to extend dogs’ healthy lifespan by targeting mechanisms of aging. | Longevity Therapeutics Developers | Series C | $100M | North America | Follow-on | age1; Baillie Gifford | Business Wire |
| L-Nutra | Jan 2026 | Science-driven nutrition-for-longevity and medical-nutrition programs, including longevity nutrition and nutrition-as-medicine therapies. | Consumer Longevity Brands | Series D+ | $36.5M | North America | Follow-on | Mubadala Investment Company | PR Newswire |
| Cirrus Therapeutics | Dec 2025 | Gene therapy targeting aging biology in dry age-related macular degeneration. | Longevity Therapeutics Developers | Seed | $11M | North America | First financing | Unknown | New Market Pitch |
| GlycanAge | Dec 2025 | Glycan-based biological-age and inflammaging diagnostics. | Diagnostics Biomarker Companies | Unknown | $8.7M | Europe | Follow-on | None clearly global tier-1 | Longevity.Technology |
| Decode Age | Dec 2025 | Longevity science company with aging biology, biomarkers, gut microbiome, and supplements. | Consumer Longevity Brands | Unknown | $1.7M | Asia-Pacific | Follow-on | None clearly tier-1 VC | Entrackr |
| Aeovian Pharmaceuticals | Dec 2025 | Selective mTORC1/CD38 therapeutics for metabolic quality control, rare and age-related diseases. | Longevity Therapeutics Developers | Series B | $55M | North America | Follow-on | Foresite; Sofinnova; venBio; Hevolution; Apollo Health Ventures | Business Wire |
| Cyclana Bio | Dec 2025 | Therapies for chronic inflammation using tissue modeling. | Longevity Therapeutics Developers | Seed | $6.6M | Europe | First financing | Unknown | New Market Pitch |
| NADMED | Dec 2025 | NAD measurement diagnostics for clinical/research use. | Diagnostics Biomarker Companies | Unknown | $3.8M | Europe | Follow-on | Unknown | New Market Pitch |
| AAA LifeOS | Nov 2025 | AI longevity and human digital continuity platform. | Aging Research Platforms | Seed | $5.6M | North America | First financing | NVentures; YZi Labs | FinancialContent |
| Function Health | Nov 2025 | Lab testing, imaging, and AI health intelligence for preventive longevity. | Preventive Health Platforms | Series B | $298M | North America | Follow-on | Redpoint; a16z; Battery; NFDG | PR Newswire |
| Blueprint | Oct 2025 | Bryan Johnson’s consumer longevity platform spanning supplements, diagnostics, prescriptions, and AI coaching. | Consumer Longevity Brands | Growth Equity | $60M | North America | First financing | Naval Ravikant; Winklevoss Capital/angels; high-profile operators rather than classic VC | Fitt Insider |
| Generation Lab | Oct 2025 | Biological-age diagnostics measuring aging across organ systems. | Diagnostics Biomarker Companies | Seed | $11M | North America | Follow-on | Accel; Samsung Next | PR Newswire |
| NewLimit | Oct 2025 | Additional epigenetic reprogramming financing. | Longevity Therapeutics Developers | Unknown | $45M | North America | Follow-on | Lilly Ventures; Kleiner Perkins; Section 32; Dimension | Ventureburn |
| Vincere Biosciences | Oct 2025 | Small molecules restoring mitophagy for aging and Parkinson’s. | Longevity Therapeutics Developers | Unknown | $5M | North America | Follow-on | Unknown | New Market Pitch |
| Illimis Therapeutics | Sep 2025 | TAM receptor-targeting therapies for Alzheimer’s and immune disease. | Longevity Therapeutics Developers | Series A | $42M | North America | Follow-on | Unknown | New Market Pitch |
| Jocasta Neuroscience | Sep 2025 | Klotho protein therapy for cognitive decline and dementia. | Longevity Therapeutics Developers | Series A | $35M | North America | First financing | Unknown | New Market Pitch |
| MitoRx Therapeutics | Aug 2025 | Mitochondrial-protective therapeutics targeting sulfide-signaling dysfunction. | Longevity Therapeutics Developers | Unknown | $2.1M | Europe | Follow-on | Unknown | New Market Pitch |
| Matter Bio | Aug 2025 | Preclinical longevity drugs for cancer and aging biology. | Longevity Therapeutics Developers | Unknown | $7M | North America | Follow-on | Unknown | New Market Pitch |
| Fountain Life | Aug 2025 | AI-enabled preventive longevity clinics and diagnostics. | Healthy Aging Clinics | Series B | $18M | North America | Follow-on | Unknown | TechCrunch |
| Blue Longevity Clinic | Jul 2025 | Clinic focused on longevity services. | Healthy Aging Clinics | Unknown | $2.3M | Europe | First financing | None clearly tier-1 global | Gaebler |
| Everlab | Jul 2025 | AI-powered preventive health and longevity diagnostics platform/clinic model. | Preventive Health Platforms | Seed | $10M | Asia-Pacific | First financing | Left Lane Capital | Business Wire |
| Circulate Health | Jul 2025 | Therapeutic plasma exchange network and research for healthspan/biological age. | Healthy Aging Clinics | Seed | $12M | North America | First financing | Khosla Ventures | PR Newswire |
| Genflow Biosciences | Jun 2025 | SIRT6 gene therapy approach to decelerate aging. | Longevity Therapeutics Developers | Unknown | $4.3M | Europe | Follow-on | Unknown | New Market Pitch |
| Biopeak | Jun 2025 | Indian wellness/longevity platform. | Preventive Health Platforms | Seed | $3M | Asia-Pacific | First financing | Accel-linked angel Prashanth Prakash; Rainmatter | Economic Times |
| Minovia Therapeutics | May 2025 | Mitochondrial augmentation therapies relevant to age-related decline. | Longevity Therapeutics Developers | Series D+ | $180M | Asia-Pacific | Follow-on | Unknown | New Market Pitch |
| Juvenescence | May 2025 | AI-enabled therapeutics targeting core aging mechanisms and age-related diseases. | Longevity Therapeutics Developers | Series B | $76M | Europe | Follow-on | M42 | PharmiWeb |
| NewLimit | May 2025 | Epigenetic reprogramming medicines to restore youthful cell function. | Longevity Therapeutics Developers | Series B | $130M | North America | Follow-on | Kleiner Perkins; Khosla Ventures; Founders Fund | TechCrunch |
| Insilico Medicine | Mar 2025 | AI drug discovery platform with aging-related disease focus. | Aging Research Platforms | Series D+ | $110M | Asia-Pacific | Follow-on | Value Partners Group; Qiming-linked prior backers | PR Newswire |
| Loyal | Feb 2025 | FDA-pathway drugs to extend healthy canine lifespan. | Longevity Therapeutics Developers | Series B | $22M | North America | Follow-on | Valor Equity Partners | Longevity.Technology |
| Junevity | Feb 2025 | siRNA cell-reset therapeutics for diseases of aging and healthspan. | Longevity Therapeutics Developers | Seed | $10M | North America | First financing | None clearly tier-1 | Business Wire |
| Retro Biosciences | Jan 2025 | Cellular reprogramming, autophagy, and plasma-inspired therapies to extend healthy lifespan. | Longevity Therapeutics Developers | Series A / Unknown | $1,000M | North America | Follow-on | Sam Altman as high-profile backer, not a VC firm | TechCrunch |
| Grey Matter Neurosciences | Jan 2025 | Focused ultrasound neurotechnology for Alzheimer’s and age-related brain disease. | Longevity Therapeutics Developers | Seed | $14M | North America | First financing | None clearly tier-1 VC | Newswire.ca |
| Cambrian Bio | Jan 2025 | Longevity therapeutics platform targeting biological drivers of aging. | Longevity Therapeutics Developers | Unknown | $23M | North America | Follow-on | Unknown | Crain’s New York |
| Arda Therapeutics | Oct 2024 | Targeted cell-depletion therapies for chronic diseases and aging-related pathogenic cells. | Longevity Therapeutics Developers | Series A | $43M | North America | Follow-on | Andreessen Horowitz Bio + Health; GV; Eli Lilly; Two Sigma Ventures | Arda Therapeutics |
| clock.bio | Oct 2024 | Healthspan biotech decoding human rejuvenation biology and identifying potential gene-therapy targets for rejuvenation. | Aging Research Platforms | Seed | $5.3M | Europe | First financing | LocalGlobe; BlueYard Capital | Business Wire |
| Integrated Biosciences | Oct 2024 | Synthetic biology and machine-learning platform for next-generation therapeutics targeting age-related diseases. | Aging Research Platforms | Seed | $17.2M | North America | First financing | Sutter Hill Ventures; Illumina Ventures Labs; Mission BioCapital; Lifespan Vision Ventures | Business Wire |
| HDAX Therapeutics | Sep 2024 | HDAC6-targeted therapies for neurological and cardiometabolic disease, framed within longevity/age-related therapeutic development. | Longevity Therapeutics Developers | Seed | $3.2M | North America | First financing | FACIT; TIAP | Business Wire |
| NADMED | Aug 2024 | Blood-test technology for NAD and glutathione status, positioned as a personalized diagnostics tool connected to age-related degenerative disease biology. | Diagnostics Biomarker Companies | Series A | $3.8M | Europe | Follow-on | Voima Ventures; Nordic Science Investments | Cision |
| Human Longevity, Inc. | Aug 2024 | AI-driven longevity medicine/precision prevention platform and clinic network. | Healthy Aging Clinics | Series B | $39.8M | North America | Follow-on | TVM Capital Healthcare; Panacea Venture | PR Newswire |
| Oisín Biotechnologies | Jul 2024 | Genetic medicines for age-related diseases, including programs addressing unwanted fat cells and frailty/muscle mass. | Longevity Therapeutics Developers | Series A | $15M | North America | Follow-on | AbbVie Ventures | FirstWord Pharma |
| Function Health | Jun 2024 | Whole-body preventive health/testing platform offering broad biomarker panels and personalized health insights; longevity coverage frames the company around helping people live 100 healthy years. | Preventive Health Platforms | Series A | $53M | North America | Follow-on | Andreessen Horowitz Bio + Health | MobiHealthNews |
| Alzheon | Jun 2024 | Clinical-stage biopharma developing oral Alzheimer’s disease therapeutics and diagnostics for neurodegenerative disease; included as a longevity-focused therapeutic financing. | Longevity Therapeutics Developers | Series D+ | $100M | North America | Follow-on | Alerce Medical Technology Partners | Alzheon |
| Matter Bio | May 2024 | Biotech focused on preserving genome integrity and extending healthy human lifespan. | Longevity Therapeutics Developers | Seed | $7M | North America | First financing | Lifespan Vision Ventures | PR Newswire |
| Humanaut Health | May 2024 | Longevity and health-optimization clinic platform combining advanced diagnostics, medical oversight, and membership-based longevity care. | Healthy Aging Clinics | Seed | $8.7M | North America | First financing | None clearly tier-1 by global venture standard | Business Wire |
| Rubedo Life Sciences | Apr 2024 | Biopharma developing therapies targeting senescent/pathologic cells that drive aging and age-related disease. | Longevity Therapeutics Developers | Series A | $40M | North America | Follow-on | Khosla Ventures; Hevolution; R42 Group | Business Wire |
| Aeovian Pharmaceuticals | Mar 2024 | Clinical-stage biotech developing selective mTORC1 inhibitors; mTOR biology is a central aging/longevity pathway, although the immediate clinical focus includes rare and age-related diseases. | Longevity Therapeutics Developers | Series A | $50M | North America | Follow-on | Hevolution; Sofinnova Investments; venBio | PR Newswire |
| SENISCA | Mar 2024 | RNA-based senotherapeutics for age-related disease. | Longevity Therapeutics Developers | Seed | $4.7M | Europe | Follow-on | R42 Group; Lifespan Vision Ventures | SENISCA |
| PreemptiveAI | Mar 2024 | Biomedical foundation model for health prediction and monitoring from smartphone/wearable physiological signals, positioned around extending human life and proactive risk detection. | Preventive Health Platforms | Seed | $6.4M | North America | First financing | Inspired Capital; Precursor Ventures | PR Newswire |
| GlycanAge | Feb 2024 | Glycan biomarker testing company for biological age and personalized preventive health. | Diagnostics Biomarker Companies | Seed | $4.2M | Europe | Follow-on | None clearly tier-1 by global standard | EU-Startups |
| BioAge Labs | Feb 2024 | Clinical-stage biotech developing therapeutics by harnessing the biology of aging, including azelaprag for metabolic disease/body composition. | Longevity Therapeutics Developers | Series D+ | $170M | North America | Follow-on | Sofinnova Investments; RA Capital; Eli Lilly; Amgen Ventures | BioSpace |
| Vasa Therapeutics | Jan 2024 | Preclinical biopharma developing therapies for cardiovascular aging, including HFpEF and frailty-related age-related disease. | Longevity Therapeutics Developers | Seed | $6M | North America | First financing | None clearly tier-1 by global venture standard | PR Newswire |
INSIGHTS
The insights below come from reviewing publicly disclosed qualifying equity rounds in pure-play longevity companies across full-year 2024, full-year 2025, and year-to-date 2026 through May 2026.
- Total capital is a poor standalone indicator for the longevity market because one or two rounds can completely change the annual picture. Full-year 2025 looked like a $2.212B market, but Retro Biosciences alone represented about 45% of that total. Always read the total alongside the total excluding the largest deal.
- The median round is a better indicator of the typical company's fundraising reality than the average round. The 2024 median was $11.9M and the 2025 median was $12.0M, even though average round size more than doubled. That means the typical financing environment changed far less than the headline market size suggests.
- The longevity market has a persistent formation-versus-scale split. First financings represented 38.9% of 2024 deals, 35.5% of 2025 deals, and 40.0% of year-to-date 2026 deals, but first financings captured less than 10% of capital in every period.
- The core underwriting question has shifted from whether longevity is interesting to whether a longevity company can prove something measurable. The largest rounds consistently attach to regulatory milestones, therapeutic mechanisms, biomarker systems, clinical workflows, or scalable preventive-health infrastructure.
- Therapeutics are not merely one category inside the longevity market; therapeutics are the market's capital spine. They captured about three-quarters or more of capital in every observed period, which means every other category should be interpreted relative to therapeutics rather than as an equal peer.
- The longevity market is not anti-consumer, but it is skeptical of consumer-only longevity. Blueprint and L-Nutra show that consumer-facing companies can raise large rounds, but the evidence favors exceptional brand pull, clinical scaffolding, or medical-nutrition credibility over generic supplement positioning.
- Diagnostics are strategically important but financially underweighted. Biological-age testing and biomarker measurement are central to the longevity story, yet Diagnostics Biomarker Companies captured only about 1% to 1.5% of annual capital in 2024 and 2025 and had no qualifying 2026 deal through May.
- The market seems to value diagnostics more as infrastructure than as standalone category winners. Function Health's large preventive-platform round suggests that biomarker data becomes more fundable when embedded inside a broader longitudinal health platform.
- Clinics are investable but not yet capital-dominant. Healthy Aging Clinics appear across the period, but their low capital share suggests investors still need proof that clinic models can scale beyond high-end service delivery into data, network, or platform economics.
- North America remains the longevity market's default scale geography. Even when Asia-Pacific and Europe contribute meaningful deal counts, the largest checks still overwhelmingly cluster in North America.
- Europe is active but undercapitalized. Europe had 22.6% of 2025 deals but only 4.7% of capital, which suggests European longevity companies are often funded as scientific options rather than as globally scaled category leaders.
- Asia-Pacific's 2025 emergence was real but not yet stable. Moving from zero capital in 2024 to about $305M in 2025 is meaningful, but the early-2026 signal is only one $7M deal, so the region still needs repeat large rounds to confirm durable momentum.
- The market's capital concentration is not a temporary artifact. Concentration appears in 2024, intensifies in 2025, and remains extreme in early 2026, which suggests a structural winner-takes-most dynamic rather than a one-year anomaly.
- The bottom half of companies are increasingly starved relative to the top. The bottom half of deals captured 8.5% of 2024 capital and only 4.2% of 2025 capital, meaning incremental market growth did not improve conditions for the long tail.
- Repeat investor activity remains surprisingly thin for a market with large headlines. The absence of repeat disclosed investors in early 2026 and limited repeat activity in 2025 suggest longevity is not yet a deeply routinized deployment category for most investors.
- Longevity-specialist investors matter, but generalist and biotech investors define the largest rounds. The most capitalized companies tend to attract firms with broader biotech, healthcare, AI, or institutional mandates, not only longevity-native funds.
- The market's most credible companies convert aging into familiar investment grammar. Drug development, FDA pathways, clinical endpoints, platform data, and recurring preventive-health workflows are easier to fund than abstract promises of longer life.
- The absence of Series A and Series B rounds in early 2026 is one of the most important warning signs. Seed and late-stage funding can coexist without proving that the market has a healthy progression path from formation to scaling.
- The longevity market is more advanced scientifically than commercially. The financing evidence contains many mechanisms and platforms, but fewer signals of standardized reimbursement, endpoint consensus, or repeatable commercial adoption.
- Veterinary longevity may become a serious proving ground rather than a side category. Loyal's repeated fundraising and FDA-pathway framing show that animal longevity can offer clearer endpoints and shorter regulatory timelines than human lifespan extension.
- The strongest forecasting rule is to separate longevity exposure from longevity investability. A company becomes more investable when longevity is attached to a measurable intervention, regulated product, defensible platform, or repeatable care pathway.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this longevity funding tracker by reviewing publicly disclosed equity rounds raised by pure-play longevity companies across full-year 2024, full-year 2025, and year-to-date 2026 through May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to extending healthspan, slowing aging, improving biological resilience, preventing age-related decline, measuring biological age, or developing longevity medicine through science, medicine, or technology.
We applied four core filters. First, we only included equity rounds, so grants, debt, structured financings, public offerings, SPAC transactions, acquisitions, and business combinations are excluded. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play longevity companies and excluded generic healthcare, wellness, beauty, fitness, eldercare, wearable, and disease-first companies that lacked explicit longevity or healthspan positioning. Fourth, every entry had to be confirmed by a direct company announcement, press release, tier-1 media report, specialized industry source, or relevant regional publication.
Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics such as total capital, average round size, median round size, and capital share by category. We kept disclosed-amount deals even when stage information was incomplete, but the 2026 year-to-date sample contains no unknown-stage qualifying rounds.
For the 2026 year-to-date period, the final qualifying sample contains 5 disclosed equity rounds across 5 unique companies. Near misses were excluded when the company was aging-adjacent but not more than 80% focused on longevity or healthspan, including broad wearables, cognitive assessment, regenerative medicine, immunology, presbyopia, and neurodegeneration companies without a strict longevity-market fit.
Related blog posts
- The latest developments shaping the longevity market
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The most recent funding news in the longevity market
- The evolution of funding activity in the longevity market
- The startups that have raised the most funding in the longevity market
